Riskpilot← Back to searchSign inGet full accessCadix Med AB
ABActiveOrg 5591169130Sandfjärdsgatan 12Medical specialists activities · NACE 8622Est. 20171-4 employees
Revenue 2025
SEK 1,8M
-12% vs 2024
EBITDA margin
19.5%
-13% vs 2024
Equity ratio
50.3%
Financial strength
Net profit 2025
SEK 282K
-37% vs 2024
| Revenue | SEK 1,8M | -12% |
| EBITDA | SEK 355K | -13% |
| Net profit | SEK 282K | -37% |
| Total assets | SEK 2M | +7% |
| Equity | SEK 1M | +9% |
| Employees | — | — |
Legal name
Cadix Med AB
Org number
5591169130
Legal form
Aktiebolag
NACE code
8622 · Medical specialists activities
Founded
27 juni 2017
Share capital
SEK 50 000
Employees
1-4
VAT registered
Yes
Audit selected
No
Last report
2025-12-31
Financial year
January – December
Signatory rights
Firman tecknas av styrelsen Firman tecknas var för sig av ledamöterna
Company purpose
Bolagets verksamhet består i mottagningsverksamhet, medicinsk rådgivning och analys, föreläsaruppdrag samt övrig konsultverksamhet inom offentlig och privat sektor inom de medicinska specilatieternainternmedicin, endokrinologi och diabetologi, kardiologi samt allmänmedicin.
Address
Sandfjärdsgatan 12
Email
sergej.scheel@yahoo.se
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Revenue | 1 440 | 1 645 | 1 688 | 2 066 | 1 815 |
| Staff expenses | — | — | −1 071 | −1 687 | −1 352 |
| EBITDA | 653 | 216 | 494 | 407 | 355 |
| Depreciation & amort. | −0 | −0 | — | — | — |
| EBIT | 653 | 216 | 494 | 407 | 355 |
| Net financials | −2 | — | −4 | −1 | 1 |
| Profit before tax | 652 | 216 | 489 | 575 | 356 |
| Tax | −128 | −44 | −102 | −127 | −74 |
| Net profit | 524 | 172 | 387 | 449 | 282 |
| Item | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|
| Total assets | 1 358 | 1 523 | 1 599 | 1 896 | 2 031 |
| Equity | 613 | 605 | 692 | 940 | 1 022 |
| Long-term debt | 0 | 0 | — | — | — |
| Short-term debt | 473 | 646 | 636 | 853 | 905 |
| Total debt | 473 | 646 | 636 | 853 | 905 |
EBITDA margin
19.5%
This company
15.8%
Market median
+23% vs market
20212025
Equity ratio
50.3%
This company
38.2%
Market median
+32% vs market
20212025
Return on equity
27.6%
This company
18.4%
Market median
+50% vs market
20212025
Net profit margin
15.5%
This company
8.1%
Market median
+91% vs market
20212025
Asset turnover
0.89×
This company
1.12×
Market median
+21% vs market
20212025
Debt / equity
0.99×
This company
0.62×
Market median
+60% vs market
20212025
- Annual report 2025Filed via Bolagsverket / SCB · Period 2025-01-01 – 2025-12-31
- Annual report 2024Filed via Bolagsverket / SCB · Period 2024-01-01 – 2024-12-31
- Annual report 2023Filed via Bolagsverket / SCB · Period 2023-01-01 – 2023-12-31
- Annual report 2022Filed via Bolagsverket / SCB · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Bolagsverket / SCB · Period 2021-01-01 – 2021-12-31
No data on file.
| Name | Role | Member since |
|---|---|---|
| Current (3) | ||
| Board of Directors | 2022 | |
| Chairman | 2022 | |
| Deputy Board Member | 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of Cadix Med AB also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Maria Rosa Rabadan Climent | Board of Directors | 0 companies |
| Sergej Ditlev Victor Manuel Scheel | Chairman | 0 companies |
| A J Adriano J D J Bermudez-Gonzalez | Deputy Board Member | 0 companies |